Introduction: This study aims to determine the Acinetobacter sp clinical isolates frequency and its antibiotic susceptibility pattern by comparing
Introduction
Acinetobacter is a non-fermenting Gram negative coccobacillus with a high capacity to colonize the human body and the environmental reservoirs [1] . It has become over the past three decades a major associated care infections agent with a high morbidity and a high mortality rate especially in immunocompromised patients ranging from 26.5 to 91% [2] [3] [4] [5] . In Morocco, a retrospective study [6] from 2002 to 2005 showed that this bacterium represented 13.63% of clinical isolates from blood cultures in the intensive care units (ICUs) [6] and in another Moroccan study [7] , it represented 6.74% of all Gram-negative bacilli. The Acinetobacter infection prevalence is variable depending on the geographical localization and the patient's socio-economic status [8] [9] [10] . In an international study in ICUs, the Acinetobacter infections rate was 19.2% in Asia; 17.1% in Eastern Europe; 14.8% in Africa; 13.8% in Central and South America; 5.6% in Western Europe; 4.4% in Oceania and 3.7% in North America [10] . It is 15% in South African HIV-positive patients [8] and 13% in Canadian burn care units [9] . In our region, no studies on Acinetobacter prevalence have been performed. Acinetobacter is an opportunistic pathogen known for its intrinsic resistance to antibiotics and greater ability to rapidly acquire resistance genes as mobile genetic elements (plasmids, transposons, integrons cassettes and insertion sequences) [11] [12] [13] .
Multidrug resistant (MDR) Acinetobacter baumannii is becoming a global threat with a therapeutic impasse increasingly described in literature [14] [15] [16] . Indeed this organism generally has resistance to several antibiotics. According to the literature data, the resistance rate varies from 31. 
Results

Characteristics of Acinetobacter´s clinical isolates
During the study period, 441clinical isolates of Acinetobacter were collected, representing 6.94% of all bacterial isolates (n=6352) and 9.6% of all Gram-negative bacilli (n=4569) throughout the hospital. isolates (n=974) and 31.5% of all Gram-negative bacilli (n=769).
They were collected from 156 patients infected with Acinetobacter.
For these patients 61.53% were male with a sex ratio of 1.6 and represented a 49.2% of patients with bacterial infection (n=317). In the other units, 199 isolates of Acinetobacter were collected, representing 3.7% of all isolates (n=5378) and 5.23% of Gramnegative rods (n=3800) obtained in these units. These isolates were obtained from 137 infected patients. Among these patients, 69.3%
were male, so a sex ratio equal to 2.3 and represented a rate of 4.2% of whole patients with bacterial infection (n=3248). The difference in the prevalence of Acinetobacter related-infections between the ICUs and the other units was statistically significant (p <0.001). Figure 1 shows the overall sensitivity patterns of clinical isolates of Acinetobacter sp with the resistance rate to colistin of 1.7%. The resistance rates difference between the ICUs and the other units was statistically significant (p< 0.05) except for colistin, tetracycline and rifampicin ( 
Antibiotic susceptibility
Discussion
The present study shows that the infection Acinetobacter 's prevalence in HMIMV is high with higher rates in ICUs compared to other units (p <0.001). The isolation rate of Acinetobacter in the various samples was 6.94%.These results are higher compared to those from the study conducted by Mushtaq and al. (2013) [14] in Pakistan where the isolation rate of Acinetobacter species was 4.2% [11] . In an international study on the prevalence of infections in ICUs in 75 countries [10] , the isolation rate of Acinetobacter (8.8%) was significantly lower than that of the ICUs (24.85 %) in our hospital. These clinical isolates represented 9.6% of all gramnegative bacilli in the hospital and 31.5% in the ICUs. On the other hand, a study carried out in an Indian hospital reported a comparable rate as A. baumannii constituted 9.4% of all Gramnegative rods throughout the hospital and 22.6% in the ICUs [20] .
Our study shows that the frequency and resistance of . This high prevalence observed in our study is probably related to non-compliance with the recommendations for mastery the hospital environment [24] , lack in hands hygiene and misuse of antibiotics [25] . Some studies have reported that this microorganism which has emerged worldwide as a pathogen causing serious infections in hospitalized patients has the ability to persist in the environment for a long period of time, colonize patients or healthy subjects and can develop into a true infection at any time [26] . Since hand transmission is a major factor in the spread of this pathogen [24] , hand hygiene and disinfection of equipment/environment are the two most important factors to control and prevent the outbreak of an epidemic Acinetobacter [24] .
In our study, 65.2% of affected patients were male. The predominance of male patients infected with Acinetobacter has been verified in other studies but the reason is not justified [2, 3, 5, 11].
The average age of patients in our study was 54 years (2-101 years) with predominance of patients over 17 years; these results are similar to those of many authors [2, 3, 5, 11]. The old age of patients was recognized as an independent risk factor of the acquisition of A. baumannii infection [5] . Many authors have reported the predominance of Acinetobacter strains in bronchopulmonary samples [7, 20, 27] . In this study, the main isolation site of these clinical isolates was also broncho-pulmonary (44.67%) hands of healthcare workers [3, 24] . For the beta-lactam antibiotics which are a large family playing an important role in antimicrobial treatment [31] , the high resistance of Acinetobacter clinical isolates to this class of antibiotics (ceftazidime, cefepime, imipenem and piperacillin / tazobactam) has been described in the literature [31] .
In our study, the resistance rate against tested beta-lactam antibiotics ranged from 76% to 89% throughout the hospital, from 87 to 98% in the ICUs and 59-75% in the other units. This rate is comparable to that observed in Asia, where it ranged from 56 to 94% [14, 20, 27, 32] . In a Libyan study, the resistance was of 62.3 to 98.8% throughout the studied hospital, 71.6-100% in the ICUs and from 42.6 to 96.2% in the other units [31] . The resistance to ceftazidime and cefepime was 86%. In the ICUs, the resistance rate to ceftazidime was 95.8% and 72.2% in the other units. This rate is higher than that obtained in the United States and South Africa in a similar study where the resistance to ceftazidime was 52.1% and 68.4% respectively [8, 21] . It ranges from 60 to 92.1% in studies in
Asia [14, 20, 27, 32] .
Carbapenems (imipenem, meropenem) remain one of the most important therapeutic options for these infections despite the fact that carbapenem-resistant strains are increasing [25] . In our study, [18, 21] . Carbapenem resistance in A.
baumannii is often due to the expression of OXA carbapenemase types, Metallo-beta-lactamases (MBL) carbapenemase and the impermeability associated with mutations altering the expression of porins and efflux pumps [3, 30] . In this study, most of cephalosporinase production were predominant with a rate of 33% [22] . In a Tunisian study, the majority of A. baumannii trains had the penicillinase phenotype in 26.3% of cases [19] . This emphasizes the alarming increase in resistance to imipenem and the expression of carbapenemase often related to the misuse of this antibiotic class in the clinical departments of our hospital. For the aminoglycosides, netilmicin was the most effective with a resistance rate of 33.07% against 43.03% for tobramycin and 52.28% for amikacin. Our data are different and lower than those obtained by Jaggi and al. (2012) in India; where resistance to tobramycin, gentamicin, netilmicin and amikacin were 80.0, 85.8, 90.3 and 90.3% respectively [19] . The aminoglycosides resistance in Acinetobacter spp. involves the production of aminoglycosides modifying enzymes and genes encoding these enzymes can be acquired through plasmids, transposons or integrons [3, 20] . The rate of resistance to ciprofloxacin observed in our study (87.7%). This rate is comparable to that reported in the literature which varies from 28.8 to 91.6% [8, [17] [18] [19] [20] . The prescription of this drug in the treatment of Acinetobacter infections is rare because of the high resistance to this antibiotic in our institution. Rifampicin was very effective (but less than colistin) with a resistance rate of 32.11%, but the use of this drug in the treatment of Acinetobacter infections is limited because Morocco is a country of endemic tuberculosis. Colistin was the most active antibiotic against Acinetobacter. In this study, the resistance to colistin was 1.7%.
Some studies have reported that no clinical isolate of Acinetobacter was resistant to colistin [13, 22] but the resistance to colistin has been described in India, South Africa and Korea [20, 33] . Several authors confirm that colistin remains the only option for empirical treatment of serious Acinetobacter infections in cases where this bacterium is strongly suspected to be resistant to other antibiotics [12, 19] . The mechanism of resistance to this antibiotic is rare and may be explained by the loss of lipopolysaccharide and/or deployment of a system of twocomponent regulatory PmrAB [34, 35] . Synergy between colistin and rifampicin or anti-Pseudomonas carbapenem is described in some studies [25] . There are no specific recommendations regarding the combination of antibiotics for the treatment of these serious infections due to the lack of prospective comparative clinical trials with a control group [25] . The combination therapy used in 
Conclusion
In this study, we showed that, in our hospital, the frequency and rates of MDR Acinetobacter infection are high and could pose a real problem and a management impasse. A strict control of the hospital environment, hand hygiene and optimizing the use of antibiotics is recommended in order to reduce the MDR frequency.
What is known about this topic
 Acinetobacter is a non-fermenting Gram negative coccobacillus with a high capacity to colonize the human body and the environmental reservoirs and it is associated with a high morbidity and a high mortality rate especially in immunocompromised patients.
 Acinetobacter is an opportunistic pathogen known for its intrinsic resistance to antibiotics and greater ability to rapidly acquire resistance genes.  This study shows that the frequency and resistance of Acinetobacter isolates are increasing in our hospital.
 This is the first Moroccan study that reports the rate of MDR Acinetobacter .
The infection Acinetobacter's prevalence and the MDR Acinetobacter rate were statically higher in the intensive care units compared to other units.
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